Dostarlimib achieved complete remission of colorectal cancer in all patients in a study

Elimination of tumors after 6 months of treatment with PD-1 blockade allowed us to skip both chemoradiation and surgery and move forward only with observation.

The study also provides a framework for evaluating highly active cancer therapies in the new adjuvant setting. Photo: shutterstock.

The study conducted in the United States and published in The New England Journal of Medicineled by a team from Memorial Sloan Kettering Cancer Center (MSK) in New York, was performed on a small sample of only 18 people, and the results will have to be replicated to ensure they are equivalent to treatment.

Despite this, these early results indicate that the treatment is surprisingly effective, and the research team says successful cancer cures have been seen in all The patients Who participated in the trial may not be History of pharmacological interventions against cancer.

“I think this is the first time this has happened in the history of cancer,” says Luis Diaz Jr. of MSK, one of the study’s authors and lead author of the article that published the findings.

The patients Those who participated in this study, sponsored by GlaxoSmithKline, did so as an alternative to other more invasive treatments such as radiation therapy or chemotherapy.

Related news

According to studies, genetic mutations can be a therapeutic target for head and neck cancer

The cancer disappeared in all of them and could not be detected either by physical examination, endoscopy, or through tomography positron emission tomography or magnetic resonance imaging.

The drug, whose trade name is Jemperli, is an immunotherapy used to treat endometrial cancer. This was the first clinical investigation aimed at finding out if it was Effective against colon and rectal tumors. Its mechanism of action depends on exposure to cancerous cellsThis allows the immune system to recognize and destroy it. was administered to The patients every three weeks and costs about $11,000 per dose.

Another noteworthy aspect of the study is that none of the trial participants experienced significant clinical complications, despite the fact that one in five patients usually had some adverse reaction to inhibitory drugs such as dustarlimab.

“In this study of patients with locally advanced rectal cancer that lacks repair, treatment with neo-adjuvant PD-1 blockade alone resulted in a complete clinical response, as measured by Rectal MRI combinationEndoscopic visual examination and digital rectal examination, in 12 patients who underwent follow-up of at least 6 months. The integrity of these responses is supported by the absence of tumor Residual in endoscopic biopsies on the sequencing and accuracy of FDG uptake in positron emission tomography scans,” the researchers revealed in the published paper.

In conclusion, the study achieved elimination of tumors after 6 . Months of blockage treatment From PD-1 it allowed us to skip both chemo-radiation and surgery and move on to just observation. Surgery and radiation can have lasting effects on fertility, sexual health, and bowel and bladder function.

“The implications for quality of life are significant, particularly among patients in whom standard therapy may impair their ability to have children. With the increased incidence of rectal cancer among young people of childbearing age, use of PD-1 blockade to eliminate the need for chemoradiation and surgery may confer a benefit.” Especially in that age group,” they say.

Source consult here.